azd-1480
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00910728)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Also potent inhibitor of JAK1
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1- Mol. weight
- 348.77 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1231124 ↗
Also known as
- 5-chloro-n2-(1-(5-fluoropyrimidin-2-yl)ethyl)-n4-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine
- azd1480
- azd1480
- azd1480
- azd 1480
- azd-1480
- azd-1480
- azd-1480
- azd-1480
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01219543 | Phase 1 | Nov 1, 2010 | AstraZeneca, University of Ulsan |
| NCT01112397 | Phase 1 | Apr 1, 2010 | AstraZeneca |
| NCT00910728 | Phase 1 | May 1, 2009 | AstraZeneca, Icahn School of Medicine at Mount Sinai, Institut Gustave Roussy, The University of Texas, Dallas, University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2009 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2009 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2010 |
6 organizations
Page 1 / 1